nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.063	0.063	CcSEcCtD
Metaxalone—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0465	0.0465	CcSEcCtD
Metaxalone—Jaundice—Mechlorethamine—lymphatic system cancer	0.0427	0.0427	CcSEcCtD
Metaxalone—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0307	0.0307	CcSEcCtD
Metaxalone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.028	0.028	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.0227	0.0227	CcSEcCtD
Metaxalone—Leukopenia—Teniposide—lymphatic system cancer	0.0226	0.0226	CcSEcCtD
Metaxalone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0206	0.0206	CcSEcCtD
Metaxalone—Leukopenia—Fludarabine—lymphatic system cancer	0.0199	0.0199	CcSEcCtD
Metaxalone—Pruritus—Mechlorethamine—lymphatic system cancer	0.0198	0.0198	CcSEcCtD
Metaxalone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0181	0.0181	CcSEcCtD
Metaxalone—Vomiting—Mechlorethamine—lymphatic system cancer	0.0178	0.0178	CcSEcCtD
Metaxalone—Rash—Mechlorethamine—lymphatic system cancer	0.0176	0.0176	CcSEcCtD
Metaxalone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0176	0.0176	CcSEcCtD
Metaxalone—Drowsiness—Mitoxantrone—lymphatic system cancer	0.0169	0.0169	CcSEcCtD
Metaxalone—Nausea—Mechlorethamine—lymphatic system cancer	0.0166	0.0166	CcSEcCtD
Metaxalone—Jaundice—Mitoxantrone—lymphatic system cancer	0.0165	0.0165	CcSEcCtD
Metaxalone—Hypersensitivity—Teniposide—lymphatic system cancer	0.0152	0.0152	CcSEcCtD
Metaxalone—Pruritus—Teniposide—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Metaxalone—Leukopenia—Bleomycin—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Metaxalone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0134	0.0134	CcSEcCtD
Metaxalone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Metaxalone—Vomiting—Teniposide—lymphatic system cancer	0.0131	0.0131	CcSEcCtD
Metaxalone—Rash—Teniposide—lymphatic system cancer	0.013	0.013	CcSEcCtD
Metaxalone—Dermatitis—Teniposide—lymphatic system cancer	0.013	0.013	CcSEcCtD
Metaxalone—Headache—Teniposide—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Metaxalone—Pruritus—Fludarabine—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Metaxalone—Leukopenia—Carmustine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Metaxalone—Nausea—Teniposide—lymphatic system cancer	0.0122	0.0122	CcSEcCtD
Metaxalone—Leukopenia—Vincristine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Metaxalone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Metaxalone—Vomiting—Fludarabine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Metaxalone—Rash—Fludarabine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Metaxalone—Dermatitis—Fludarabine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Metaxalone—Headache—Fludarabine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Metaxalone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.0111	0.0111	CcSEcCtD
Metaxalone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Metaxalone—Nausea—Fludarabine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Metaxalone—Irritability—Methotrexate—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Metaxalone—Somnolence—Carmustine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Metaxalone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00979	0.00979	CcSEcCtD
Metaxalone—Somnolence—Mitoxantrone—lymphatic system cancer	0.00959	0.00959	CcSEcCtD
Metaxalone—Pruritus—Bleomycin—lymphatic system cancer	0.0094	0.0094	CcSEcCtD
Metaxalone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00906	0.00906	CcSEcCtD
Metaxalone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00854	0.00854	CcSEcCtD
Metaxalone—Vomiting—Bleomycin—lymphatic system cancer	0.00845	0.00845	CcSEcCtD
Metaxalone—Drowsiness—Methotrexate—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Metaxalone—Rash—Bleomycin—lymphatic system cancer	0.00838	0.00838	CcSEcCtD
Metaxalone—Dermatitis—Bleomycin—lymphatic system cancer	0.00837	0.00837	CcSEcCtD
Metaxalone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00816	0.00816	CcSEcCtD
Metaxalone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00794	0.00794	CcSEcCtD
Metaxalone—Nausea—Bleomycin—lymphatic system cancer	0.00789	0.00789	CcSEcCtD
Metaxalone—Dizziness—Carmustine—lymphatic system cancer	0.00767	0.00767	CcSEcCtD
Metaxalone—Vomiting—Carmustine—lymphatic system cancer	0.00737	0.00737	CcSEcCtD
Metaxalone—Dizziness—Vincristine—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Metaxalone—Rash—Carmustine—lymphatic system cancer	0.00731	0.00731	CcSEcCtD
Metaxalone—Dermatitis—Carmustine—lymphatic system cancer	0.00731	0.00731	CcSEcCtD
Metaxalone—Headache—Carmustine—lymphatic system cancer	0.00727	0.00727	CcSEcCtD
Metaxalone—Vomiting—Vincristine—lymphatic system cancer	0.00704	0.00704	CcSEcCtD
Metaxalone—Rash—Vincristine—lymphatic system cancer	0.00698	0.00698	CcSEcCtD
Metaxalone—Dermatitis—Vincristine—lymphatic system cancer	0.00697	0.00697	CcSEcCtD
Metaxalone—Headache—Vincristine—lymphatic system cancer	0.00694	0.00694	CcSEcCtD
Metaxalone—Nausea—Carmustine—lymphatic system cancer	0.00689	0.00689	CcSEcCtD
Metaxalone—Vomiting—Mitoxantrone—lymphatic system cancer	0.00686	0.00686	CcSEcCtD
Metaxalone—Rash—Mitoxantrone—lymphatic system cancer	0.0068	0.0068	CcSEcCtD
Metaxalone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00679	0.00679	CcSEcCtD
Metaxalone—Headache—Mitoxantrone—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Metaxalone—Nausea—Vincristine—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Metaxalone—Nausea—Mitoxantrone—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Metaxalone—Leukopenia—Methotrexate—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Metaxalone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Metaxalone—Somnolence—Methotrexate—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Metaxalone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Metaxalone—Pruritus—Methotrexate—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Metaxalone—Dizziness—Methotrexate—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Metaxalone—Vomiting—Methotrexate—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Metaxalone—Rash—Methotrexate—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Metaxalone—Dermatitis—Methotrexate—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Metaxalone—Headache—Methotrexate—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Metaxalone—Nausea—Methotrexate—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
